Revvity, Inc.(RVTY)

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Latest News & Analysis
Revvity Consolidates Software With ACD/Labs, Signaling Margin Inflection
Revvity's ACD/Labs acquisition and 20% software growth signal management confidence in margin expansion and portfolio shift toward recurring revenue.
Revvity (RVTY): Earnings, Market Trends, and Future Outlook
Revvity's Q4 earnings beat estimates but revenue lagged. Challenges in biotech spending impact outlook, while infectious disease testing offers growth. Strategic shifts are key.
Revvity (RVTY): Financial Performance, Molecular Diagnostics, and Market Outlook
Revvity's Q4 earnings beat estimates, but sales missed. The molecular diagnostics market booms, and an injunction secures software access. Strategic initiatives are crucial.
Revvity RVTY Analysis: Navigating Market Dynamics
A deep dive into Revvity's Q4 earnings, market strategies, and the impact of key industry trends. Discover actionable insights for investors.
Revvity (RVTY): Genomics England Expansion, Injunction Win, and Market Outlook
Revvity (RVTY) navigates growth opportunities and market headwinds with Genomics England expansion, Spotfire injunction win, and biotech spending slowdown.
Revvity (RVTY): Genomics England Deal, Biotech Headwinds Analysis
Revvity (RVTY) is navigating a complex market landscape. This Revvity stock analysis provides insights into its financial performance, strategic initiatives, and market outlook.
Revvity (RVTY): FDA Approval, Signals One Platform, and Market Analysis
Analysis of Revvity's (RVTY) FDA approval, Signals One platform, Genomics England alliance, financial health, and competitive landscape.
Revvity (RVTY): Advancing Diagnostics & Automation with Key Innovations
Revvity, Inc. (RVTY) is advancing oncology diagnostics and lab automation with new FDA-approved standards and platforms, signaling strategic growth.
Revvity (RVTY): Q1 Beat Signals Strategic Momentum
Revvity's Q1 2025 beat expectations, driven by diagnostics innovation and automation. Analysis of financials, strategy, and market positioning.
Revvity, Inc. Q1 2025 Analysis: Innovation Drives Diagnostics Growth Amid Market Challenges
Revvity's Q1 2025 shows robust diagnostics growth fueled by innovative oncology standards and AI drug discovery, navigating biotech funding cuts and global headwinds.
Revvity, Inc. Latest Q2 2025 Earnings Analysis: Strategic Resilience Amid Biotech Challenges
Revvity's Q2 2025 earnings reveal strategic resilience with steady revenue growth, EPS beat, and innovation in diagnostics and drug discovery software.
Revvity, Inc. Q2 2025 Analysis: Navigating China Diagnostics Challenges and Life Sciences Growth
Explore Revvity's Q2 2025 earnings beat, China diagnostics headwinds, margin pressures, and strategic initiatives shaping its future growth trajectory.
Revvity, Inc. Q2 2025 Analysis: Navigating China DRG Policy Headwinds and Strategic Growth
Explore Revvity's Q2 2025 performance amid China DRG policy challenges, strategic innovation efforts, and financial trends shaping RVTY stock's outlook.
Revvity, Inc. (RVTY) Latest Financial and Strategic Update: Earnings, Cash Flow, and Market Position Analysis
Revvity, Inc. shows mixed financial signals with steady revenue, shifting profitability, and strategic cash flow management amid evolving industry dynamics.
Revvity (RVTY): Q2 2025 — China DRG vs Life Sciences Momentum
Q2 revenue of **$720M** met growth but China DRG sent diagnostics lower; Life Sciences (Signals +30%) and $300M buybacks reshape the company’s risk/return profile.